ARCT logo

ARCT
Arcturus Therapeutics Holdings Inc

5,519
Mkt Cap
$241.6M
Volume
333,792.00
52W High
$24.17
52W Low
$5.85
PE Ratio
-3.44
ARCT Fundamentals
Price
$8.22
Prev Close
$8.50
Open
$8.46
50D MA
$7.46
Beta
1.70
Avg. Volume
575,621.95
EPS (Annual)
-$2.40
P/B
1.09
Rev/Employee
$605,594.59
$38.03
Loading...
Loading...
News
all
press releases
Hennion & Walsh Asset Management Inc. Purchases 161,910 Shares of Arcturus Therapeutics Holdings Inc. $ARCT
Hennion & Walsh Asset Management Inc. grew its position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 206.5% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 240,303 shares of the biotechnology company's stock after buying an additional 16...
MarketBeat·8d ago
News Placeholder
More News
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Share Price Passes Below 200 Day Moving Average - Should You Sell?
Arcturus Therapeutics (NASDAQ:ARCT) Stock Passes Below Two Hundred Day Moving Average - Here's What Happened...
MarketBeat·9d ago
News Placeholder
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
Arcturus Therapeutics (NASDAQ:ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payne said Arcturus had initiated a rare disease strategy for messen...
MarketBeat·18d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial
B. Riley Financial upgraded Arcturus Therapeutics to a "strong-buy" rating in a research report on Tuesday...
MarketBeat·21d ago
News Placeholder
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are currently covering the stock...
MarketBeat·21d ago
News Placeholder
Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated at B. Riley Financial
B. Riley Financial started coverage on Arcturus Therapeutics in a research report on Wednesday. They issued a "buy" rating and a $22.00 target price for the company...
MarketBeat·23d ago
News Placeholder
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics (NASDAQ:ARCT) Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA...
MarketBeat·29d ago
News Placeholder
Q1 EPS Forecast for Arcturus Therapeutics Reduced by Analyst
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Equities researchers at HC Wainwright reduced their Q1 2026 EPS estimates for shares of Arcturus Therapeutics in a research note...
MarketBeat·1mo ago
News Placeholder
Citigroup Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price
Citigroup reduced their price objective on shares of Arcturus Therapeutics from $66.00 to $21.00 and set a "buy" rating on the stock in a research report on Thursday...
MarketBeat·1mo ago
News Placeholder
Arcturus Therapeutics to Attend Upcoming Investor Conference
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today...
Business Wire·1mo ago
<
1
2
...
>

Latest ARCT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.